Axillary Lymph Node Ultrasound Following Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: Results from the SN FNAC Study

Dominique Morency MD, MSc, FRCSC, Sinziana Dumitra MD, MSc, FRCSC, Elena Parvez MD, MSc, FRCSC, Karyne Martel MD, FRCSC, Mark Basik MD, MSc, FRCSC, André Robidoux MD, FRCSC, Brigitte Poirier MD, FRCSC, Claire M. B. Holloway MD, PhD, FRCPC, Louis Gaboury MD, PhD, FRCPC, Lucas Sideris MD, FRCSC, Sarkis Meterissian MD, FRCSC, Jean-François Boileau MD, MSc, FRCSC
Breast Oncology
Volume 26, Issue 13 / December , 2019

View full article HTML | View full article PDF | Download Citation

Abstract

Background

The sentinel node biopsy following neoadjuvant chemotherapy (SN FNAC) study has shown that in node-positive (N+) breast cancer, sentinel node biopsy (SNB) can be performed following neoadjuvant chemotherapy (NAC), with a low false negative rate (FNR = 8.4%). A secondary endpoint of the SN FNAC study was to determine whether axillary ultrasound (AxUS) could predict axillary pathological complete response (ypN0) and increase the accuracy of SNB.

Methods

The SN FNAC trial is a study of patients with biopsy-proven N+ breast cancer who underwent SNB followed by completion node dissection. All patients had AxUS following NAC and the axillary nodes were classified as either positive (AxUS+) or negative (AxUS−). AxUS was compared with the final axillary pathology results.

Results

There was no statistical difference in the baseline characteristics of patients with AxUS+ versus those with AxUS−. Overall, 82.5% (47/57) of AxUS+ patients had residual positive lymph nodes (ypN+) at surgery and 53.8% (42/78) of AxUS− patients had ypN+. Post NAC AxUS sensitivity was 52.8%, specificity 78.3%, and negative predictive value 46.2%. AxUS FNR was 47.2%, versus 8.4% for SNB. If post-NAC AxUS− was used to select patients for SNB, FNR would decrease from 8.4 to 2.7%. However, using post-NAC AxUS in addition to SNB as an indication for ALND would have led to unnecessary ALND in 7.8% of all patients.

Conclusion

AxUS is not appropriate as a standalone staging procedure, and SNB itself is sufficient to assess the axilla post NAC in patients who present with N+ breast cancer.

Go to Issue Contents